Press release
Cell and Gene Therapy Market 2033: Key Drivers, Pipeline Products & Competitive Edge
FDA Approvals for Cell and Gene Therapy Market Size
Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/cell-and-gene-therapy-market?kb
United States: Recent Industry Developments
✅ December 2025: Novartis received FDA approval for a next-generation CAR-T therapy targeting solid tumors, marking a major advancement.
✅ November 2025: CRISPR Therapeutics expanded clinical trials for in vivo gene editing therapies addressing rare genetic disorders.
✅ October 2025: Bluebird Bio launched a novel gene therapy platform aimed at treating inherited blood disorders with improved safety profiles.
Japan: Recent Industry Developments
✅ December 2025: Takeda Pharmaceutical partnered with academic institutions to accelerate regenerative medicine research using iPSC technology.
✅ November 2025: Ono Pharmaceutical advanced its clinical pipeline with new gene therapies targeting neurodegenerative diseases.
✅ October 2025: Japanese regulatory agencies streamlined approval processes to support faster commercialization of cell and gene therapies.
List of Top Key Player:
Novartis AG, Gilead Sciences, Inc., Bristol Myers Squibb Company, Vertex Pharmaceuticals Incorporated, Sarepta Therapeutics, Inc., CSL Behring LLC, Amgen, Inc., Orchard Therapeutics group, Krystal Biotech, Inc., bluebird bio, Inc., and among others. Emerging market players include Editas Medicine, Intellia Therapeutics, Rocket Pharmaceuticals, Regenxbio, Affinia Therapeutics
Industry Developments:
January 2026:
1. FDA grants fast-track designation to a novel CAR-T therapy targeting solid tumors.
2. Major partnership announced between a leading biotech and a pharmaceutical giant for gene editing platform expansion.
3. New clinical trial results show improved efficacy in gene therapy for rare blood disorders.
December 2025:
1. Breakthrough in CRISPR-based therapy demonstrated in early-stage clinical trials.
2. Increased investment from venture capital in cell therapy startups focusing on autoimmune diseases.
3. Regulatory approval received for next-gen viral vectors improving delivery safety.
November 2025:
1. First-ever allogeneic stem cell therapy for heart failure enters Phase III trials.
2. Emerging markets show rising adoption of gene therapy reimbursement frameworks.
3. Key mergers and acquisitions announced, consolidating cell therapy manufacturing capabilities.
Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=cell-and-gene-therapy-market?kb
Forecast Projection:
The Global Cell and Gene Therapy Market is poised for significant growth between 2025 and 2032. In 2024, the market maintained a steady upward trajectory, and with strategic initiatives by leading players accelerating adoption, the market is expected to soar throughout the forecast period. Companies leveraging these trends are well-positioned to capture emerging opportunities and maximize revenue potential.
Market Key Segmentations:
By Therapy Type
• Cell Therapy holds a significant share, driven by advancements in stem cell research and regenerative medicine.
• Gene Therapy is rapidly growing, propelled by breakthroughs in gene editing and personalized medicine.
By Application
• Oncology dominates the market, fueled by increasing prevalence of cancer and targeted cellular treatments.
• Musculoskeletal Conditions segment grows with rising demand for regenerative therapies in orthopedic disorders.
• Ophthalmology benefits from innovative gene therapies for inherited retinal diseases.
• Blood Disorders segment expands due to advances in gene therapy for hemophilia and sickle cell disease.
• Immunodeficiency Disorders see increased adoption of cell and gene therapies improving immune system function.
• Graft-versus-host disease (GVHD) treatment market grows with improved cellular therapy options post-transplant.
• Rare Diseases segment experiences growth driven by personalized gene therapy solutions for rare genetic disorders.
• Others include emerging applications across autoimmune and metabolic diseases with promising pipeline therapies.
Regional Growth Analysis:
⇥ North America - 43.7%
Dominates due to advanced healthcare infrastructure, strong R&D, and high adoption of innovative therapies.
⇥ Europe - 28.4%
Driven by supportive regulatory frameworks, growing clinical trials, and increasing healthcare expenditure.
⇥ Asia-Pacific - 18.1%
Expanding rapidly with rising investments, improving healthcare access, and growing patient awareness.
⇥ Middle East & Africa - 5.2%
Emerging market with growing government initiatives and increasing focus on biotech innovation.
⇥ South America - 4.6%
Gradual growth supported by expanding healthcare infrastructure and increasing disease burden awareness.
Get Customization in the report as per your requirements: https://datamintelligence.com/customize/cell-and-gene-therapy-market?kb
Latest Mergers & Acquisitions Update
✦ AbbVie acquired Capstan Therapeutics for up to $2.1B (June 2025), gaining in vivo CAR-T platform (CPTX-2309 Phase I for autoimmune diseases) and RNA delivery tech for immunology/cancer.
✦ Gilead acquired Interius Biotherapeutics (Q3 2025, undisclosed), adding engineered cell therapies for solid tumors with tumor-localized delivery.
✦ Xoma acquired Generation Bio for $4.29/share plus CVR (~$200M+ potential), securing non-viral DNA medicines platform for sustained gene expression.
✦ Bristol Myers Squibb pursued gene editing assets via smaller deals (~$300M total), targeting CRISPR/Cas13 for liver-directed therapies.
✦ Cycle Pharmaceuticals acquired Applied Therapeutics ($0.088/share, December 2025) for rare disease gene modulation programs.
Request 2 Days Free Trials with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?kb
Key 2025 Approvals/Expansions
✦ Ryoncil (remestemcel-L, Mesoblast): First mesenchymal stem cell (MSC) approval for pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD) in December 2024, with 2025 label expansions.
✦ Zevaskyn (EB-101, Abeona Therapeutics): Gene-corrected autologous epidermal sheets for recessive dystrophic epidermolysis bullosa (RDEB) wounds, approved 2025 as second therapy after Vyjuvek.
✦ Encelto: First treatment for macular telangiectasia type 2 (MacTel2), marking retinal CGT milestone.
✦ Tecartus (brexucabtagene autoleucel, Kite/Gilead): Expanded March 2025 for mantle cell lymphoma, leveraging allogeneic stem cell rescue protocols.
✦ Breyanzi (lisocabtagene maraleucel, BMS): August 2025 approval for follicular lymphoma, often requiring stem cell support.
Pipeline Highlights (No BLA Approval)
✦ Deramiocel (CAP-1002, Capricor): Priority Review BLA accepted March 2025 for DMD cardiomyopathy (PDUFA August 31, 2025), followed by CRL requiring CMC resubmission.
✦ Fertilo (REPROCELL): IND cleared February 2025 for Phase III iPSC-derived ovarian support cells in fertility preservation
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.
✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring
Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cell and Gene Therapy Market 2033: Key Drivers, Pipeline Products & Competitive Edge here
News-ID: 4350757 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Intelligent Emergency Response Systems and Infrastructure Market to Reach US$ 2. …
Intelligent Emergency Response Systems and Infrastructure (IRSI) Market reached US$ 1.3 billion in 2022 and is expected to reach US$ 2.1 billion by 2030, growing at a CAGR of 6.1% during the forecast period of 2024 to 2031.
The market is experiencing steady expansion as rising urbanization, increasing frequency of natural disasters, and growing security concerns drive demand for advanced emergency response technologies. Integration of real time communication networks, smart surveillance…
Millimeter Wave Technology Market Set for Explosive Growth to USD 13.7 Billion b …
The Global Millimeter Wave Technology Market reached USD 2.8 Billion in 2023 and is expected to reach USD 13.7 Billion by 2031, growing with a CAGR of 8.2% during the forecast period 2024-2031.
Market growth is driven by surging demand for high-speed 5G networks, expanding applications in automotive radar for ADAS and autonomous vehicles, and rising adoption in security scanners and imaging systems. Advancements in semiconductor integration, government initiatives for spectrum…
Pharmacovigilance Software Market to Reach US$ 415.42 Million by 2033 at 7.4% CA …
Pharmacovigilance Software Market reached US$218.95 million in 2024 and is expected to reach US$415.42 million by 2033, growing at a CAGR of 7.4% during the forecast period of 2025 to 2033.
The market is witnessing steady growth as increasing regulatory scrutiny, rising incidence of adverse drug reactions, and the expanding volume of clinical trial and post marketing safety data drive demand for advanced pharmacovigilance solutions. Growing adoption of digital health technologies,…
Zero Trust Security Market Set for Explosive Growth to USD 92.36 Billion by 2030 …
The Zero Trust Security Market reached USD 36.89 billion in 2024 and is expected to reach USD 92.36 billion by 2030, growing at a robust CAGR of 16.5% during the forecast period 2025-2030.
Market growth is driven by the rising frequency and sophistication of cyberattacks, accelerating cloud and remote-work adoption, and the shift from perimeter-based to identity- and context-centric security architectures. Advancements in identity and access management, increasing regulatory and compliance…
More Releases for Gene
DNA and Gene Cloning Services Market Expands with Growing Focus on Complex Gene …
InsightAce Analytic Pvt. Ltd. has announced the publication of a market research report titled "Global DNA and Gene Cloning Services Market by Type of Service Offered (Custom Cloning, Sub-cloning, Gene Synthesis, and Others), Type of Gene (Complex Gene, Standard Gene, and Others), End-User Industry (Pharmaceutical, Academic and R&D, and Biotechnology Companies, and Others)- Market Outlook and Industry Analysis 2034"
The DNA and Gene Cloning Services Market Size is valued…
Evolving Market Trends In The CRISPR Gene Editing Industry: Innovative Gene Ther …
The CRISPR Gene Editing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected CRISPR Gene Editing Market Size During the Forecast Period?
The CRISPR gene editing market has grown exponentially in recent years. It will grow from $2.26 billion in 2024 to $2.88…
Cell and Gene Therapy Market Global Analysis By Type (Cell Therapy, Gene Therapy …
Gene and cell therapy uses genes and cells for the treatment of genetic diseases. Genetic diseases are caused by mutations, or errors in genes which can be passed down from one generation to another. Gene therapy aims to treat diseases by using genetic material, or DNA, to manipulate a patient's cells by replacing, changing or introducing genome into cells- either internally or externally. Cell therapy aims to treat diseases by…
Competitive and Opportunities Analysis of Gene Therapy Market of Gene Therapy Ma …
Global Gene Therapy Market accounted for US$ 2.05 billion in 2020 and is estimated to be US$ 12.29 billion by 2030 and is anticipated to register a CAGR of 19.8%. Gene therapy means fixing a working gene to an individual who features a damaged gene. The European Commission has approved this method for one particular treatment. The treatment by the merchandise Glybera uses an epidemic to infect muscle cells with…
Genetic Testing Market Size by Growth Opportunities, Top Key Players: GeneDx, In …
Genetic Testing Market Report provides an in-depth analysis of the overall market, The ripple effect of Coronavirus-Covid19 on the market needs to become part of strategy discussions to emerge strong. The report focuses on major key players, production details, their application, countries and also analyzes the global and key regions market potential and advantage, opportunity, and challenge, restraints, and risks.
The Top players Covered in report are GeneDx, Invitae, Pathway Genomics,…
Gene Synthesis Market by Top Manufacturers - Gene script, Gene Art (Thermofische …
The "Gene Synthesis Market" report Added by "Big Market Research", enumerates information about the industry in terms of market share, market size, revenue forecasts, and regional outlook. The report further illustrates competitive insights of key players in the business vertical followed by an overview of their diverse portfolios and growth strategies.
In the Gene Synthesis Market 2018 research report professionals describe the different facets of the industry with a specific goal…
